Works matching IS 14741776 AND DT 2004 AND VI 3 AND IP 3
Results: 21
Double attack on patent for Wellbutrin sustained-release agent.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 196, doi. 10.1038/nrd1336
- Publication type:
- Article
Compensation for Japanese patent holders.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 196, doi. 10.1038/nrd1337
- Publication type:
- Article
Lack of descriptive support results in no interference-in-fact.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 196, doi. 10.1038/nrd1339
- Publication type:
- Article
Scientists slam rationale behind largest HIV vaccine trial.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 195, doi. 10.1038/nrd1359
- By:
- Publication type:
- Article
NEWS IN BRIEF.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 194
- Publication type:
- Article
Aventis-Sanofi: a good R&D merger?
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 193, doi. 10.1038/nrd1358
- By:
- Publication type:
- Article
First dose of potential new medicines to humans: how animals help.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 226, doi. 10.1038/nrd1329
- By:
- Publication type:
- Article
Neurodegenerative diseases and oxidative stress.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 205, doi. 10.1038/nrd1330
- By:
- Publication type:
- Article
Case history: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 215, doi. 10.1038/nrd1331
- By:
- Publication type:
- Article
Twenty questions Highlighting the pitfalls and possibilities of drug research.
- Published in:
- 2004
- By:
- Publication type:
- Editorial
From the analyst's couch: Betting on biogenerics.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 197, doi. 10.1038/nrd1333
- By:
- Publication type:
- Article
Fresh from the pipeline: Omalizumab.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 199, doi. 10.1038/nrd1334
- By:
- Publication type:
- Article
GPCRs: Family traits.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 202, doi. 10.1038/nrd1335
- By:
- Publication type:
- Article
Target validation: Regulating the beat.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 203, doi. 10.1038/nrd1338
- By:
- Publication type:
- Article
RNA interference: Eight steps to silence.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 204, doi. 10.1038/nrd1340
- By:
- Publication type:
- Article
In Brief.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 204, doi. 10.1038/nrd1351
- Publication type:
- Article
ANTICANCER DRUGS: Overcoming inhibition.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 201, doi. 10.1038/nrd1354
- By:
- Publication type:
- Article
Cardiovascular disease: Healing hearts.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 202, doi. 10.1038/nrd1355
- By:
- Publication type:
- Article
Mining for bioinformatics jobs.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 281, doi. 10.1038/nrd1356
- By:
- Publication type:
- Article
The communication barrier: drug discovery's final frontier?
- Published in:
- 2004
- Publication type:
- Editorial
THE STATE OF ION CHANNEL RESEARCH IN 2004.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 239, doi. 10.1038/nrd1361
- By:
- Publication type:
- Article